Holen Sie sich die Stockscreener-App
64.60
5.45%
3.34
Handel nachbörslich:
65.30
0.70
+1.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$61.26
Offen:
$61.09
24-Stunden-Volumen:
2.44M
Relative Volume:
1.27
Marktkapitalisierung:
$7.90B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-12.28
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
+5.26%
1M Leistung:
-1.63%
6M Leistung:
+86.38%
1J Leistung:
+31.33%
1-Tages-Spanne:
$61.02
$64.89
1-Wochen-Bereich:
$58.85
$64.89
52-Wochen-Spanne:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
64.60 | 7.49B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Insider Sell: Andrew Callos Sells 15,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Sells $904,200.00 in Stock - MarketBeat
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire Inc.
Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat
Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com South Africa
Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed - ts2.tech
Cytokinetics, Incorporated (CYTK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - ts2.tech
Moody Aldrich Partners LLC Buys Shares of 82,460 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Stock Soars: What’s Next? - StocksToTrade
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech
Cytokinetics (NASDAQ:CYTK) Trading 3% HigherStill a Buy? - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Top Cytokinetics Insider Just Cashed Out in a High-Profile Stock Move - TipRanks
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
What Does the Market Think About Cytokinetics Inc? - Benzinga
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Cytokinetics FY2025 EPS Forecast Reduced by HC Wainwright - MarketBeat
Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Insider Sell: Wendell Wierenga Sells 20,000 Shares of Cytokineti - GuruFocus
Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics Insider Sold Shares Worth $1,322,800, According to a Recent SEC Filing - marketscreener.com
Morgan Stanley Maintains Overweight Rating on CYTK, Raises PT to $71 | CYTK Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Citizens Maintains Cytokinetics (CYTK) Market Outperform Recommendation - Nasdaq
RBC Capital Maintains Cytokinetics (CYTK) Outperform Recommendation - Nasdaq
Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha
Cytokinetics Earnings Boost After FDA Approval - StocksToTrade
Cytokinetics’ Breakthrough: Stock Set for Big Gains? - StocksToTrade
FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med - MedCity News
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - ts2.tech
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM - BioWorld MedTech
Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK) - MarketBeat
Cytokinetics jumps after FDA approves its drug for rare heart disease - TradingView — Track All Markets
Cytokinetics Surges as FDA Grants Approval for Myqorzo - timothysykes.com
Why Is Cytokinetics Stock Soaring Monday?Cytokinetics (NASDAQ:CYTK) - Benzinga
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up - Finviz
UniFirst, Adeia, Cytokinetics And Other Big Stocks Moving Higher On Monday - Benzinga
Cytokinetics stock hits 52-week high at 69.46 USD - Investing.com
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):